PRPH vs. MIST, ANIX, ONCY, SPRO, CMRX, QTTB, BRNS, VACC, ACRS, and ETON
Should you be buying ProPhase Labs stock or one of its competitors? The main competitors of ProPhase Labs include Milestone Pharmaceuticals (MIST), Anixa Biosciences (ANIX), Oncolytics Biotech (ONCY), Spero Therapeutics (SPRO), Chimerix (CMRX), Q32 Bio (QTTB), Barinthus Biotherapeutics (BRNS), Vaccitech (VACC), Aclaris Therapeutics (ACRS), and Eton Pharmaceuticals (ETON). These companies are all part of the "pharmaceutical preparations" industry.
Milestone Pharmaceuticals (NASDAQ:MIST) and ProPhase Labs (NASDAQ:PRPH) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, community ranking, analyst recommendations and earnings.
Milestone Pharmaceuticals presently has a consensus price target of $10.75, indicating a potential upside of 532.35%. ProPhase Labs has a consensus price target of $11.00, indicating a potential upside of 117.82%. Given ProPhase Labs' higher possible upside, equities research analysts clearly believe Milestone Pharmaceuticals is more favorable than ProPhase Labs.
86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.5% of ProPhase Labs shares are owned by institutional investors. 10.4% of Milestone Pharmaceuticals shares are owned by insiders. Comparatively, 26.1% of ProPhase Labs shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
In the previous week, ProPhase Labs had 6 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 7 mentions for ProPhase Labs and 1 mentions for Milestone Pharmaceuticals. Milestone Pharmaceuticals' average media sentiment score of 0.11 beat ProPhase Labs' score of 0.00 indicating that ProPhase Labs is being referred to more favorably in the news media.
Milestone Pharmaceuticals has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Comparatively, ProPhase Labs has a beta of -0.17, indicating that its stock price is 117% less volatile than the S&P 500.
ProPhase Labs has higher revenue and earnings than Milestone Pharmaceuticals. ProPhase Labs is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
ProPhase Labs received 39 more outperform votes than Milestone Pharmaceuticals when rated by MarketBeat users. However, 67.57% of users gave Milestone Pharmaceuticals an outperform vote while only 50.44% of users gave ProPhase Labs an outperform vote.
Milestone Pharmaceuticals has a net margin of 0.00% compared to Milestone Pharmaceuticals' net margin of -37.81%. Milestone Pharmaceuticals' return on equity of -29.83% beat ProPhase Labs' return on equity.
Summary
ProPhase Labs beats Milestone Pharmaceuticals on 10 of the 18 factors compared between the two stocks.
Get ProPhase Labs News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ProPhase Labs Competitors List
Related Companies and Tools
